These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

591 related articles for article (PubMed ID: 29159742)

  • 1. Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
    Baratti D; Kusamura S; Milione M; Bruno F; Guaglio M; Deraco M
    Ann Surg Oncol; 2018 Feb; 25(2):404-413. PubMed ID: 29159742
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can low grade PMP be divided into prognostically distinct subgroups based on histological features? A retrospective study and the importance of using the appropriate classification.
    Bhatt A; Mishra S; Prabhu R; Ramaswamy V; George A; Bhandare S; Shah M; Mehta S
    Eur J Surg Oncol; 2018 Jul; 44(7):1105-1111. PubMed ID: 29685759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei.
    Choudry HA; Pai RK; Shuai Y; Ramalingam L; Jones HL; Pingpank JF; Ahrendt SS; Holtzman MP; Zureikat AH; Zeh HJ; Bartlett DL
    Ann Surg Oncol; 2018 Jan; 25(1):76-82. PubMed ID: 29110275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systemic metastases from low-grade and high-grade pseudomyxoma peritonei: Treatments and outcomes.
    Baratti D; Milito P; Kusamura S; Martin Roman L; Guaglio M; Deraco M
    Eur J Surg Oncol; 2022 Jul; 48(7):1590-1597. PubMed ID: 35090796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic value of clinical and pathological characteristics in 48 women with pseudomyxoma peritonei].
    Lu YY; Guo AT; Liu AJ; Shi HY
    Zhonghua Fu Chan Ke Za Zhi; 2013 Aug; 48(8):595-601. PubMed ID: 24199925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the significance of pseudomyxoma peritonei patients based on the Peritoneal Surface Oncology Group International (PSOGI) classification.
    Lee JL; Kim M; Kim J; Kim CW; Ha YJ; Kim SY; Cho DH; Kim JC
    Asian J Surg; 2021 Jun; 44(6):848-853. PubMed ID: 33622598
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.
    Baratti D; Kusamura S; Milione M; Pietrantonio F; Caporale M; Guaglio M; Deraco M
    Ann Surg Oncol; 2016 Dec; 23(13):4222-4230. PubMed ID: 27352203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A single-center clinical analysis of 65 cases of pseudomyxoma peritonei from appendiceal origin in the early stage].
    Ma RQ; Xia A; Zhai XC; Chen F; Xu HB
    Zhonghua Zhong Liu Za Zhi; 2019 Sep; 41(9):698-702. PubMed ID: 31550861
    [No Abstract]   [Full Text] [Related]  

  • 9. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified?
    López-López V; Cascales-Campos PA; Gil E; Arevalo J; Gonzalez A; Gil J; Muñoz-Casares FC; Melero JT; Barrios P; Morales R; Ramos I; Ortega G; Camps B; González-Bayón L; Bretcha-Boix P; Farré-Alegre J; González-Moreno S; Parrilla P
    Clin Transl Oncol; 2017 Nov; 19(11):1388-1392. PubMed ID: 28812240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative safety after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei from appendiceal origin: Experience on 254 patients from a single center.
    Li XB; Ma R; Ji ZH; Lin YL; Zhang J; Yang ZR; Chen LF; Yan FC; Li Y
    Eur J Surg Oncol; 2020 Apr; 46(4 Pt A):600-606. PubMed ID: 31973925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrence and outcome after complete tumour removal and hyperthermic intraperitoneal chemotherapy in 512 patients with pseudomyxoma peritonei from perforated appendiceal mucinous tumours.
    Lord AC; Shihab O; Chandrakumaran K; Mohamed F; Cecil TD; Moran BJ
    Eur J Surg Oncol; 2015 Mar; 41(3):396-9. PubMed ID: 25216980
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) in pseudomyxoma peritonei of appendiceal origin: result of a single centre study.
    Di Leo A; Corvasce A; Weindelmayer J; Mason EJ; Casella F; de Manzoni G
    Updates Surg; 2020 Dec; 72(4):1207-1212. PubMed ID: 32410159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival after complete cytoreductive surgery and HIPEC for extensive pseudomyxoma peritonei.
    Benhaim L; Faron M; Gelli M; Sourrouille I; Honoré C; Delhorme JB; Elias D; Goere D
    Surg Oncol; 2019 Jun; 29():78-83. PubMed ID: 31196498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin.
    Delhorme JB; Severac F; Averous G; Glehen O; Passot G; Bakrin N; Marchal F; Pocard M; Lo Dico R; Eveno C; Carrere S; Sgarbura O; Quenet F; Ferron G; Goéré D; Brigand C;
    Br J Surg; 2018 May; 105(6):668-676. PubMed ID: 29412465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellularity in low-grade Pseudomyxoma peritonei impacts recurrence-free survival following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
    Horvath P; Yurttas C; Birk P; Struller F; Königsrainer A
    Langenbecks Arch Surg; 2018 Dec; 403(8):985-990. PubMed ID: 30506401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications and outcomes for repeat cytoreductive surgery and heated intra-peritoneal chemotherapy in peritoneal surface malignancy.
    Sutton PA; O'Dwyer ST; Barriuso J; Aziz O; Selvasekar CR; Renehan AG; Wilson MS
    Surg Oncol; 2021 Sep; 38():101572. PubMed ID: 33915487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei.
    Sørensen O; Andersen AM; Larsen SG; Giercksky KE; Flatmark K
    Clin Exp Metastasis; 2019 Dec; 36(6):511-518. PubMed ID: 31541325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative study of mucinous and non-mucinous appendiceal neoplasms with peritoneal dissemination treated by cyoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC).
    Garach NR; Kusamura S; Guaglio M; Bartolini V; Deraco M; Baratti D
    Eur J Surg Oncol; 2021 May; 47(5):1132-1139. PubMed ID: 33280949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histologic Predictors of Recurrence in Mucinous Appendiceal Tumors with Peritoneal Dissemination after HIPEC.
    Reghunathan M; Kelly KJ; Valasek MA; Lowy AM; Baumgartner JM
    Ann Surg Oncol; 2018 Mar; 25(3):702-708. PubMed ID: 29282599
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mucinous appendiceal neoplasms: classification, imaging, and HIPEC.
    Bartlett DJ; Thacker PG; Grotz TE; Graham RP; Fletcher JG; VanBuren WM; Iyer VR; Fidler JL; Menias CO; Wasif N; Sheedy SP
    Abdom Radiol (NY); 2019 May; 44(5):1686-1702. PubMed ID: 30610247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.